Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the presence, degree, time course and profile of
opioid withdrawal symptoms associated with induction onto new formulations of buprenorphine
or buprenorphine/naloxone in persons with active opioid dependence. The primary outcome
measure is the severity of withdrawal symptoms measured using the Clinical Opiate Withdrawal
Scale (COWS). The primary study hypothesis is that neither drug formulation will precipitate
an opioid withdrawal syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Indivior Inc.
Treatments:
Analgesics, Opioid Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone